Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea

NCT01973218 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01973218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01973218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2013
Completion date
April 30, 2014
Enrollment
264 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease